Author

Davide Giuseppe Ribaldone 1

1 University of Turin,Turin,Italy

CELIAC DISEASE AMONG A LARGE INFLAMMATORY BOWEL DISEASE POPOULATION: EPIDEMIOLOGY AND OUTCOME

Marco Astegiano, Davide Giuseppe Ribaldone, Marta Vernero, Gabriele Giudici, Francesco Maria Stalla, Camilla Dutto, Rinaldo Pellicano, Gian Paolo Caviglia, Giorgio Saracco, Elisabetta Bugianesi

DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE

Giuseppe Privitera, Sara Onali, Daniela Pugliese, Sara Renna, Edoardo Savarino, Anna Viola, Davide Giuseppe Ribaldone, Andrea Buda, Cristina Bezzio, Gionata Fiorino, Massimo Claudio Fantini, Franco Scaldaferri, Luisa Guidi, Silvio Danese, Antonio Gasbarrini, Ambrogio Orlando, Alessandro Armuzzi

EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

Ahmad Albshesh, Joshua Taylor, Edoardo Vincenzo Savarino, Marie Truyens, Alessandro Armuzzi, Davide Giuseppe Ribaldone, Ariella Shitrit, Morine Fibelman, Pauliina Molander, Claire Liefferinckx, Stephane Nancy, Mohamed Korani, Klaudia Farkas, Manuel Barreiro de Acosta, Viktor Domislovic, Gerard Surís, Carl Eriksson, Catarin

INTERLEUKINS LEVELS: ARE WE ON THE ROAD TO TAILORED THERAPY IN INFLAMMATORY BOWEL DISEASE?

Marta Vernero, Davide Giuseppe Ribaldone, Martina Rizzo, Gian Paolo Caviglia, Francesco Maria Stalla, Giorgio Maria Saracco, Marco Astegiano

MULTIPLE SCLEROSIS PREVALENCE IN HIGHER IN CROHN’S DISEASE PATIENTS THAN IN GENERAL POPULATION, BUT DOES NOT INFLUENCE INFLAMMATORY BOWEL DISEASE OUTCOME

Francesco Maria Stalla, Davide Giuseppe Ribaldone, Marta Vernero, Valentina Schillaci, Paola Cavalla, Rinaldo Pellicano, Marco Astegiano, Giorgio Saracco, Elisabetta Bugianesi

Item 1 - 5 / 5
1